National Breast and Cervical Cancer Act allowed states federal waivers to spend a greater share of funds on underserved women
| | | | | | |

National Breast and Cervical Cancer Act allowed states federal waivers to spend a greater share of funds on underserved women

On Apr. 20, 2007, the National Breast and Cervical Cancer Early Detection Program Reauthorization Act of 2007 allowed…

FDA approved trastuzumab for use with other drugs in adjuvant treatment of women with early-stage, node-positive, HER2-overexpressing breast cancer
| | | | | | |

FDA approved trastuzumab for use with other drugs in adjuvant treatment of women with early-stage, node-positive, HER2-overexpressing breast cancer

On Nov. 16, 2006, the U.S. Food and Drug Administration (FDA) approved Genentech’s trastuzumab (Herceptin) for use with…

NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence
| | | | | | |

NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence

In 2006, the National Cancer Institute (NCI) launched the TAILORx trial to determine whether gene expression patterns in…